Prioritising access to cancer drugs

Lancet Oncol. 2022 Jan;23(1):e2. doi: 10.1016/S1470-2045(21)00637-9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Health Services Accessibility
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents